LENZ Therapeutics, Inc. (LENZ) Accumulated Expenses (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed Accumulated Expenses for 2 consecutive years, with $3.8 million as the latest value for Q2 2023.
- On a quarterly basis, Accumulated Expenses changed N/A to $3.8 million in Q2 2023 year-over-year; TTM through Jun 2023 was $3.8 million, a N/A change, with the full-year FY2022 number at $3.8 million, changed N/A from a year prior.
- Accumulated Expenses was $3.8 million for Q2 2023 at LENZ Therapeutics, up from $1.3 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $3.8 million in Q4 2022 to a low of $1.3 million in Q1 2023.